

PERSONAL INFORMATION **Patricia McGettigan**WORK EXPERIENCE

- August 2016- Present **Associate Professor Clinical Pharmacology and Medical Education**
Queen Mary University of London (United Kingdom)
Research: drug utilisation; medicines adverse effects; medicines regulation Teaching: QMUL Head of MBBS clinical pharmacology and therapeutics teaching; Module lead, Clinical Trials and Regulatory affairs
Clinical: Consultant Physician at Barts Health NHS Trust
- October 2011-July 2016 **Senior lecturer in Clinical Pharmacology**
Queen Mary University of London (United Kingdom)
Research & teaching
- October 2011- Present **Consultant Physician, Barts Health NHS Trust**
Queen Mary University of London (United Kingdom)
In-patient and out-patient clinical care in cardiology and HIV-metabolic medicine, including in 2020, inpatient care for patients with COVID-19
- July 2006-September 2011 **Senior Lecturer in Medicine and Medical Education**
Hull York Medical School, University of Hull and University of York (United Kingdom)
Research & teaching
- July 2006-September 2011 **Honorary Consultant Physician, North Lincolnshire and Goole Hospitals NHS Foundation Trust**
Hull York Medical School, University of Hull and University of York (United Kingdom)
Out-patient clinical care
- February 2001-June 2006 **Senior Lecturer & Staff Specialist**
School of Medicine and Public Health, University of Newcastle; Calvary Mater Hospital, New South Wales, Australia (Australia)
Research & teaching; In-patient and out-patient clinical care
- August 1997-January 2001 **Research Academic; Medicines Evaluator; Registrar in Clinical Toxicology; Senior Medical Registrar**
In-patient and out-patient clinical care (Australia)
Research & teaching; Medicines Evaluation; In-patient and out-patient clinical care
- August 1993-July 1997 **Medical Registrar and MD candidate**
Departments of General Medicine and Pharmacology and Therapeutics, St. James Hospital and University of Dublin, Trinity College, Dublin, Ireland (Ireland)
MD: 'Pharmacoepidemiology - an Irish perspective' research; MBBS student teaching; In-patient and out-patient clinical care

EDUCATION AND TRAINING

- August 1993-June 1997 **Doctor of Medicine**
University of Dublin, Trinity College (Ireland)
Pharmacoepidemiology; drug utilisation; adverse events; clinical medicine
- October 1984-June 1990 **MB, BCh, BAO, BA**
University of Dublin, Trinity College (Ireland)
Medicine
- October 1977-June 1981 **BSc (Pharmacy)**
University of Dublin, Trinity College (Ireland)

ADDITIONAL INFORMATION

Expertise Patient registries - During the period September 2016 until December 2018, on secondment (80%) from Queen Mary University of London, I worked with the Pharmacovigilance and Epidemiology Division at EMA. I led the patient registries initiative, liaising with EMA's cross-committee task force on patient registries and multiple internal and external stakeholders to organise disease-specific patient registry workshops in cystic fibrosis, multiple sclerosis, CAR-T cell therapies and haemophilia. The work has established a network of registry holders, marketing authorisation holders, patient groups, healthcare professionals and regulatory experts keen to harness the potential of patient registries to support regulatory decision-making. The resulting reports, publications, registry inventory, scientific opinions, and presentations are available at <https://www.ema.europa.eu/en/human-regulatory/post-authorisation/patient-registries>; Pharmacoepidemiology, drug utilisation studies, medicines-associated adverse events - please refer to publications list

Publications

Holt A, Blanche P, Jensen AKG, et al. Adverse events associated with co-prescription of phosphodiesterase type 5 inhibitors and oral organic nitrates in male patients with ischemic heart disease: A case-crossover study. *Ann Intern Med.* (2022). doi: 10.7326/M21-3445. PMID: 35436155.

Morales DR, Moreno-Martos D, Matin M, McGettigan P. Health conditions in adults with HIV compared with the general population: A population-based cross-sectional analysis. (2022) *Lancet EClinicalMedicine* 47, 101392

Holt A, Blanche P, Zareini B, et al. (2022) Gastrointestinal bleeding risk following concomitant treatment with oral glucocorticoids in patients on non-vitamin K oral anticoagulants. *Heart*; 108:626-632.

Jonker CJ, de Vries ST, van den Berg HM, et al. (2021). Capturing Data in Rare Disease Registries to Support Regulatory Decision Making: A Survey Study Among Industry and Other Stakeholders. *Drug Saf.* 44(8):853-861. doi: 10.1007/s40264-021-01081-z

Holt A, Blanche P, Jensen AKG, Nouhravesh N, Rajan D, Jensen MH, El-Sheikh M, Schjerning AM, Schou M, Gislason G, Torp-Pedersen C, McGettigan P, Lamberts M. Adverse events associated with co-prescription of phosphodiesterase type 5 inhibitors and oral organic nitrates in male patients with ischemic heart disease: A case-crossover study. *Ann Intern Med.* (2022). doi: 10.7326/M21-3445. PMID: 35436155.

Holt A, Blanche P, McGettigan P, Lamberts M (2021). Temporal changes in myocardial infarction diagnostic criteria do not account for the lack of long-term beta-blocker effect on cardiovascular prognosis. *Eur Heart J* 10.1093/eurheartj/ehab260

Holt A, Blanche P, Zareini B, Rajan D, El-Sheikh M, Schjerning AM, Schou M, Torp-Pedersen C, McGettigan P, Gislason GH, Lamberts M. (2021). Effect of long-term beta-blocker treatment following myocardial infarction among stable, optimally treated patients without heart failure in the reperfusion era: a Danish, nationwide cohort study. *Eur Heart J.* Vol. 42, (9): 907 - 914. 10.1093/eurheartj/ehaa1058

Hodges G, Pallisgaard J, Schjerning Olsen AM, McGettigan P, Andersen M, Krogager M, Kragholm K, Kober L et al. (2020) . Association between biomarkers and COVID-19 severity and mortality: A nationwide Danish cohort study. *BMJ Open* vol. 10 , (12) 10.1136/bmjopen-2020-041295

Robson J, Moss N, McGettigan P, Beardsley SJ, Lovegrove E, Dezateux C (2020) . First do no harm: Valproate and medicines safety in pregnancy. *British Journal of General Practice* vol. 70, (699) 477 - 478. 10.3399/bjgp20X712673

McGettigan P, Ferner RE (2020) . Painful perianal ulcers with nicorandil. *The BMJ* vol. 370. 10.1136/bmj.m3351

Schjerning AM, McGettigan P, Gislason G (2020) . Cardiovascular effects and safety of (non-aspirin) NSAIDs. *Nature Reviews Cardiology* vol. 17 (9) 574 - 584. 10.1038/s41569-020-0366-z

Lovegrove E, Robson J, McGettigan P (2020) . Pregnancy protection and pregnancies in women prescribed ACE inhibitors or ARBs: A cross-sectional study in primary care. *British Journal of General Practice* vol. 70 (700) 10.3399/BJGP20X712997

Ferner R, McGettigan P (2020) . The patient who reports a drug allergy. *The BMJ* vol. 368. 10.1136/bmj.l6791

Schjerning Olsen AM, McGettigan P, Gislason G. (2020) Cardiovascular effects and safety of (non-aspirin) NSAIDs. *Nature Reviews Cardiology*; <https://doi.org/10.1038/s41569-020-0366-z>

Ferner RE, McGettigan P. (2020) Drug allergies. *BMJ*; 368 doi: <https://doi.org/10.1136/bmj.l6791>

Schjerning Olsen AM, McGettigan P, Gerds TA, Fosbol EL, Olesen JB, Sindet-Pedersen C, Staerk L, Hansen ML, Pallisgaard JL, Kober L, Torp-Pedersen C, Gislason GH, Lamberts M. (2019) Risk of gastrointestinal bleeding associated with oral anticoagulation and non-steroidal anti-inflammatory drugs in patients with atrial fibrillation: a nationwide study. *European Heart Journal - Cardiovascular Pharmacotherapy* [shttps://doi.org/10.1093/ehjcvp/pvz069](https://doi.org/10.1093/ehjcvp/pvz069)

Schuster Bruce C, Brhlikova P, Heath J, McGettigan P. (2019) The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011-2018. *PLoS Med.* 2019; 16(9):e1002873. doi:10.1371/journal.pmed.1002873

McGettigan P, Alonso CO, Plueschke K, Castillon M, Noguera DZ, Bahri P, Kurz X, Mol P. (2019) Patient registries: an underused resource for medicines evaluation: operational proposals for increasing the use of patient registries in regulatory assessments. *Drug Safety* 2019; 42:1343-51. <https://doi.org/10.1007/s40264-019-00848-9>.

Barcella CA, Lamberts M, McGettigan P, et al. (2019) Differences in cardiovascular safety with non-steroidal anti-inflammatory drug therapy-A nationwide study in patients with osteoarthritis. *Basic Clin Pharmacol Toxicol.* 2019; 124: 629- 641. <https://doi.org/10.1111/bcpt.13182>

Alonso Olmo C, McGettigan P, Kurz X. (2019) Barriers and opportunities for use of patient registries in medicines regulation. *Clin Pharmacol Ther.* 2019; 106(1): 39-42

Morales D, Pacurariu A, Slattery J, Pinheiro L, McGettigan P, Kurz X. (2019) Association between peripheral neuropathy and exposure to oral fluoroquinolone or co-amoxiclav therapy: population-based nested case-control study. *JAMA Neurol.* 2019;76(7):827-833. doi:10.1001/jamaneurol.2019.0887

Ferner RE, McGettigan P. (2018) Adverse Drug Reactions. *BMJ*; 363:k4051. doi: 10.1136/bmj.k4051. PMID: 30401691.

Pacurariu A, Plueschke K, McGettigan P, et al. (2018) Electronic healthcare databases in Europe: descriptive analysis of characteristics and potential for use in medicines regulation. *BMJ Open* <https://bmjopen.bmj.com/content/8/9/e023090>

Plueschke K, McGettigan P, Pacurariu A, Kurz X, Cave A. (2018) EU-funded initiatives for Real World Evidence: Descriptive analysis of their characteristics and relevance for regulatory decision-making. *BMJ Open* <https://bmjopen.bmj.com/content/8/6/e021864.info>

McGettigan P, Roderick P, Kadam A et al. (2018). Threats to global antimicrobial resistance control: Centrally approved and unapproved antibiotic formulations sold in India. *Br J Clin Pharmacol* 10.1111/bcp.13503

McGettigan P, Roderick P, Kadam A et al. (2017). Access, Watch, and Reserve antibiotics in India: challenges for WHO stewardship. *The Lancet Global Health* vol. 5, (11) e1075-e1076. 10.1016/S2214-109X(17)30365-0

McGettigan P, Olsen A-MS. (2017). NSAIDs for high-risk patients: none, celecoxib, or naproxen?. *Lancet* vol. 389, (10087) 2351-2352. 10.1016/S0140-6736(17)30980-7

McGettigan P, Ferner RE. (2017). PCSK9 inhibitors for hypercholesterolaemia. *BMJ* vol. 356, 10.1136/bmj.j188

McGettigan P, McKendree J. (2016). Presence of medical students and length of stay in the Emergency Department. *JAMA* vol. 315, (18), 10.1001/jama.2016.1577

McGettigan P, McKendree J. (2015). Interprofessional training for final year healthcare students: A mixed methods evaluation of the impact on ward staff and students of a two-week placement and of factors affecting sustainability. *BMC Med Educ* vol. 15, 10.1186/s12909-015-0436-9

Schjerning Olsen A-M, Lindhardsen J, Gislason GH, McGettigan P et al. (2015). Impact of proton pump inhibitor treatment on gastrointestinal bleeding associated with non-steroidal anti-inflammatory drug use among post-myocardial infarction patients taking antithrombotics: nationwide study. *BMJ* vol. 351, 10.1136/bmj.h5096

McGettigan P, Roderick P, Mahajan R et al.(2015). Use of Fixed Dose Combination (FDC) Drugs in India: Central Regulatory Approval and Sales of FDCs Containing Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Metformin, or Psychotropic Drugs. *PLoS Med* vol. 12, (5) 10.1371/journal.pmed.1001826

Schjerning Olsen A-M, Gislason GH, McGettigan P et al. (2015). Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial

infarction. JAMA vol. 313, (8) 805-814. 10.1001/jama.2015.0809

McGettigan P, Pollock A, Herxheimer A. (2014). Department of Health's misguided alert recommending neuraminidase inhibitors for flu. BMJ vol. 348, 10.1136/bmj.g1594

Roderick P, Mahajan R, McGettigan P et al. (2014). India should introduce a new Drugs Act. Lancet vol. 383, (9913) 203-206, 10.1016/S0140-6736(14)60059-3

Herxheimer A, McGettigan P. (2013). Problems of polypharmacy. BMJ vol. 347, 10.1136/bmj.f7500

McGettigan P, McKendree J, Reed N et al. (2013). Identifying attributes required by Foundation Year 1 doctors in multidisciplinary teams: a tool for performance evaluation. BMJ Qual Saf vol. 22, (3) 225-232, 10.1136/bmjqs-2012-001418

McGettigan P, Henry D. (2013). Use of non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle-, and high-income countries. PLoS Med vol. 10, (2), 0.1371/journal.pmed.1001388

McGettigan P, Lincz LF, Attia J et al. (2011). The risk of coronary thrombosis with cyclo-oxygenase-2 inhibitors does not vary with polymorphisms in two regions of the cyclo-oxygenase-2 gene. BRIT J CLIN PHARMACO vol. 72, (4) 707-714, 10.1111/j.1365-2125.2011.03957.x

McGettigan P, Henry D. (2011). Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med vol. 8, (9) 10.1371/journal.pmed.1001098

McGettigan P, Henry D. (2011). Cardiovascular Events after Prescription of NSAIDs - Updated Systematic Review of Pharmaco-Epidemiological Studies. PHARMACOEPIDEM DR S vol. 20, S324-S325.

Waring WS, McGettigan P. (2011). Clinical toxicology and drug regulation: A United Kingdom perspective. CLIN TOXICOL vol. 49, (6) 452-456, 0.3109/15563650.2011.594054

McGettigan P, Henry D. (2011). Evaluation of cardiovascular risk with NSAIDs: Limitations arising from inconsistent reporting in pharmacoepidemiological studies. BASIC CLIN PHARMACOL vol. 109, 139-139.

McGettigan P, Henry D. (2011). Pharmacoepidemiological studies advance the information from randomized trials investigating nsaid associated cardiovascular risk. BASIC CLIN PHARMACOL vol. 109, 25-25.

Ringland C, Mant A, McGettigan P et al. (2008). Uncovering the potential risk of serotonin toxicity in Australian veterans using pharmaceutical claims data. BRIT J CLIN PHARMACO vol. 66, (5) 682-688. 10.1111/j.1365-2125.2008.03253.x

McGettigan P, Han P, Jones L et al. (2008). Selective COX-2 inhibitors, NSAIDs and congestive heart failure: differences between new and recurrent cases. Br J Clin Pharmacol vol. 65, (6) 927-934. 10.1111/j.1365-2125.2008.03121.x

Attia J, Thakkinstian A, Wang Y et al. (2007). The PAI-1 4G/5G gene polymorphism and ischemic stroke: an association study and meta-analysis. J Stroke Cerebrovasc Dis vol. 16, (4) 173-179. 10.1016/j.jstrokecerebrovasdis.2007.03.002

Henry D, McGettigan P. (2007). Selective COX-2 inhibitors: A promise unfulfilled?. GASTROENTEROLOGY vol. 132, (2) 790-794, 10.1053/j.gastro.2007.01.017

McGettigan P, Henry D. (2006). Cardiovascular risk and inhibition of cyclooxygenase - A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase. JAMA-J AM MED ASSOC vol. 296, (13) 1633-1644, 10.1001/jama.296.13.jrv60011

Moxey AJ, Adams CA, McGettigan P. (2006). Making treatment decisions for cancer: What do patients consider?. PSYCHO-ONCOL vol. 15, (2) S338-S339.

McGettigan P, Han P, Henry D(2006). Cyclooxygenase-2 inhibitors and coronary occlusion - exploring dose-response relationships. Br J Clin Pharmacol vol. 62, (3) 358-365. 10.1111/j.1365-2125.2006.02660.x

Robertson J, McGettigan P. (2006). What price research? Aust Fam Physician vol. 35, (1-2)

Robertson J, Walkom EJ, McGettigan P. (2005). Response rates and representativeness: a lottery incentive improves physician survey return rates. PHARMACOEPIDEM DR S vol. 14, (8) 571-577. 10.1002/pds.1126

McGettigan P, Henry D(2005). Medical research and the news media. NEW ENGL J MED vol. 352, (8) 838-838, 10.1056/NEJM200502243520821

Moxey A, O'Connell D, McGettigan P et al. (2003). Describing treatment effects to patients. J Gen Intern Med vol. 18, (11) 948-959, 10.1046/j.1525-1497.2003.20928.x

Henry D, McGettigan P. (2003). Epidemiology overview of gastrointestinal and renal toxicity of

NSAIDs. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE. 43-49.

Isbister GK, Whyte IM, Downes F et al. (2003). Concomitant overdosing of other drugs in patients with paracetamol poisoning. *Br J Clin Pharmacol* vol. 55, (3) 325-325. 10.1046/j.1365-2125.2003.01761.x

Henry D, McGettigan P. (2003). Upper gastrointestinal event risk with COX-2 inhibitors depended on known risk factors. *ACP J Club* vol. 138, (2)

Isbister GK, McGettigan P, Harris I. (2003). Hyperbaric oxygen for acute carbon monoxide poisoning. *N Engl J Med* vol. 348, (6) 557-560, 10.1056/NEJM200302063480615

McGettigan P, Isbister GK, Whyte IM. (2003). Adolescent depression. *NEW ENGL J MED* vol. 348, (5) 473-473, 10.1056/NEJM200301303480521

Isbister GK, McGettigan P, Dawson A. (2001). A fatal case of moclobemide-citalopram intoxication. *J ANAL TOXICOL* vol. 25, (8) 716-717, 10.1093/jat/25.8.716

McGettigan P, Golden J, Fryer J et al. (2001). Prescribers prefer people: The sources of information used by doctors for prescribing suggest that the medium is more important than the message. *Br J Clin Pharmacol* vol. 51, (2) 184-189, 10.1111/j.1365-2125.2001.01332.x

Smith AJ, McGettigan P. (2000). Quality use of medicines in the community: the Australian experience. *Br J Clin Pharmacol* vol. 50, (6) 515-519, 10.1046/j.1365-2125.2000.00291.x

McGettigan P, Kelly A, Carvahlo M et al.(2000). Anti-depressants in primary care: Analysis of treatment discontinuations. *PHARMACOEPIDEM DR S* vol. 9, (6) 521-528. 10.1002/1099-1557(200011)9:6<521::AID-PDS525>3.0.CO;2-K

McGettigan P, Henry D. (2000). Current problems with non-specific COX inhibitors. *CURR PHARM DESIGN* vol. 6, (17) 1693-1724, 10.2174/1381612003398690

McGettigan P. (2000). COX-2 inhibitors. What is their place?. *Aust Fam Physician* vol. 29, (9) 847-852.

Feely T, McGettigan P, Kelly A. (2000). Growth in use of statins after trials is not targeted to most appropriate patients. *CLIN PHARMACOL THER* vol. 67, (4) 438-441, 10.1067/mcp.2000.105152

McGettigan P, Sly K, O'Connell D et al. (1999). The effects of information framing on the practices of physicians. *J GEN INTERN MED* vol. 14, (10) 633-642, 10.1046/j.1525-1497.1999.09038.x

Henry D, McGettigan P. (1999). Cardiac and renal failure due to NSAIDs: a review of the epidemiological literature. *Inflammopharmacology* vol. 7, (3) 311-338. 10.1007/s10787-999-0015-y

McGettigan P, Henry D, Page J. (1998). Adverse effects of non-steroidal anti-inflammatory drugs on the gastrointestinal tract and kidney: relationship to cyclooxygenase-2 selectivity. Book Chapter: CLINICAL SIGNIFICANCE AND POTENTIAL OF SELECTIVE COX-2 INHIBITORS. Editors: Vane, JR, Botting, RM, 149-160.

Belton KJ, Gram LF, Royer RJ et al. (1997). Attitude survey of adverse drug-reaction reporting by health care professionals across the European Union. *EUR J CLIN PHARMACOL* vol. 52, (6) 423-427. 10.1007/s002280050314

McGettigan P, Mooney EE, Sinnott M et al. (1997). Sudden death in Whipple's disease. *POSTGRAD MED J* vol. 73, (862) 509-511, 10.1136/pgmj.73.862.509

McGettigan P, Golden J, Conroy RM et al. (1997). Reporting of adverse drug reactions by hospital doctors and the response to intervention. *Br J Clin Pharmacol* vol. 44, (1) 98-100. 10.1046/j.1365-2125.1997.00616.x

McGettigan P, McManus J, OShea B et al. (1997). Low rate of generic prescribing in the Republic of Ireland compared to England and Northern Ireland: Prescribers' concerns. *IRISH MED J* vol. 90, (4) 146-147.

Hemeryck L, McGettigan P, Feely J. (1997). Hospital antibiotic prescribing and feedback. *Br J Clin Pharmacol* vol. 43, (4) 449-450.

Wen Y, Killalea S, McGettigan P et al. (1996). Lipid peroxidation and antioxidant vitamins C and E in hypertensive patients. *IRISH J MED SCI* vol. 165, (3) 210-212, 10.1007/BF02940252

Lee TC, O'Driscoll KJ, McGettigan P et al.(1988). The site of the tendinous interruption in semitendinosus in man. *J ANAT* vol. 157, 229-231.

Projects Prioritising Medicines to Meet Public Health Needs: I am currently working with colleagues in the UK and India on sales and regulation of fixed dose combination medicines in India

I collaborated on work examining the use of fixed dose combination drugs associated with the AMASA (Accessing Medicines in Africa and South Asia) project, funded under the FP7 scheme (EU FP7 Health-2009-4.3.2-2

(Grant 242262)) (See also publication list)

HIV co-morbidities - currently working with Barts Health NHS Trust and University of Dundee colleagues on a study of co-morbidities among patients in the UK living with HIV

Memberships Medical Board of New South Wales, Australia: Specialist registration in General Medicine & Clinical Pharmacology
Medical Council of Ireland: Fully registered medical practitioner; Specialist registration in Clinical Pharmacology
General Medical Council, England: Fully registered medical practitioner with a license to practice; Specialist registration in Clinical Pharmacology
Fellowship; Royal Australasian College of Physicians
Fellowship; Royal College of Physicians of Ireland
Senior Fellowship; The Higher Education Academy, United Kingdom.
Fellowship: British Pharmacological Society

Other Relevant Information